JP2015501840A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501840A5 JP2015501840A5 JP2014547353A JP2014547353A JP2015501840A5 JP 2015501840 A5 JP2015501840 A5 JP 2015501840A5 JP 2014547353 A JP2014547353 A JP 2014547353A JP 2014547353 A JP2014547353 A JP 2014547353A JP 2015501840 A5 JP2015501840 A5 JP 2015501840A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- seq
- sequence encoding
- subunit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims description 404
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 347
- 239000012634 fragment Substances 0.000 claims description 253
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 claims description 107
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 claims description 107
- 102000014154 Interleukin-12 Subunit p35 Human genes 0.000 claims description 105
- 108010011301 Interleukin-12 Subunit p35 Proteins 0.000 claims description 105
- 102000004169 proteins and genes Human genes 0.000 claims description 76
- 108090000623 proteins and genes Proteins 0.000 claims description 76
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 57
- 108020004707 nucleic acids Proteins 0.000 claims description 57
- 102000039446 nucleic acids Human genes 0.000 claims description 57
- 108091026890 Coding region Proteins 0.000 claims description 36
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 34
- 230000002163 immunogen Effects 0.000 claims description 20
- 239000013612 plasmid Substances 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 230000028993 immune response Effects 0.000 claims description 12
- 201000009182 Chikungunya Diseases 0.000 claims description 6
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 6
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 6
- 241000711920 Human orthopneumovirus Species 0.000 claims description 6
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 6
- 241000700647 Variola virus Species 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 206010022000 influenza Diseases 0.000 claims description 6
- 201000004792 malaria Diseases 0.000 claims description 6
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 244000052769 pathogen Species 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 5
- 238000004520 electroporation Methods 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- -1 SEQ ID NO: 2 amino acids Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 241000700605 Viruses Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569600P | 2011-12-12 | 2011-12-12 | |
| US61/569,600 | 2011-12-12 | ||
| PCT/US2012/069017 WO2013090296A1 (en) | 2011-12-12 | 2012-12-11 | Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018084090A Division JP6803354B2 (ja) | 2011-12-12 | 2018-04-25 | 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501840A JP2015501840A (ja) | 2015-01-19 |
| JP2015501840A5 true JP2015501840A5 (enExample) | 2016-01-21 |
| JP6333730B2 JP6333730B2 (ja) | 2018-05-30 |
Family
ID=48613120
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547353A Active JP6333730B2 (ja) | 2011-12-12 | 2012-12-11 | 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| JP2018084090A Active JP6803354B2 (ja) | 2011-12-12 | 2018-04-25 | 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| JP2020198052A Active JP7129106B2 (ja) | 2011-12-12 | 2020-11-30 | 改善されたｉｌ－１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| JP2022129334A Withdrawn JP2022160704A (ja) | 2011-12-12 | 2022-08-15 | 改善されたｉｌ－１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| JP2024109421A Pending JP2024138373A (ja) | 2011-12-12 | 2024-07-08 | 改善されたｉｌ－１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018084090A Active JP6803354B2 (ja) | 2011-12-12 | 2018-04-25 | 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| JP2020198052A Active JP7129106B2 (ja) | 2011-12-12 | 2020-11-30 | 改善されたｉｌ－１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| JP2022129334A Withdrawn JP2022160704A (ja) | 2011-12-12 | 2022-08-15 | 改善されたｉｌ－１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| JP2024109421A Pending JP2024138373A (ja) | 2011-12-12 | 2024-07-08 | 改善されたｉｌ－１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9272024B2 (enExample) |
| EP (2) | EP2791157A4 (enExample) |
| JP (5) | JP6333730B2 (enExample) |
| KR (5) | KR102101819B1 (enExample) |
| CN (1) | CN104245719B (enExample) |
| AU (1) | AU2012352457B2 (enExample) |
| BR (1) | BR112014014078A2 (enExample) |
| CA (1) | CA2858893A1 (enExample) |
| EA (1) | EA026926B1 (enExample) |
| MX (2) | MX354986B (enExample) |
| WO (1) | WO2013090296A1 (enExample) |
| ZA (1) | ZA201404199B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2791157A4 (en) | 2011-12-12 | 2015-10-14 | Univ Pennsylvania | COMPOSITIONS WITH IMPROVED GENETIC IL-12 CONSTRUCTS AND VACCINES, IMMUNOTHERAPY THEREOF AND METHOD OF USE THEREOF |
| WO2014151279A1 (en) * | 2013-03-15 | 2014-09-25 | The Trustees Of The University Of Pennsylvania | Vaccines having an antigen and interleukin-23 as an adjuvant |
| MX383277B (es) * | 2015-01-09 | 2025-03-13 | Oncosec Medical Inc | Plasmido que codifica a un agonista coestimulador. |
| WO2016170176A1 (en) | 2015-04-22 | 2016-10-27 | Curevac Ag | Rna containing composition for treatment of tumor diseases |
| EP3458083B1 (en) | 2016-05-18 | 2022-11-02 | ModernaTX, Inc. | Polynucleotides encoding interleukin-12 (il12) and uses thereof |
| US10888594B2 (en) | 2016-05-30 | 2021-01-12 | National University Corporation Tottori University | Genetically engineered vaccinia viruses |
| US20190336552A1 (en) | 2016-05-30 | 2019-11-07 | Astellas Pharma Inc. | Genetically engineered vaccinia viruses |
| CN106520779A (zh) * | 2016-11-09 | 2017-03-22 | 华南农业大学 | 一种通过密码子优化鸡il‑2基因提高鸡的il‑2蛋白表达效率的方法 |
| US11421011B2 (en) | 2017-05-18 | 2022-08-23 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| JP7484717B2 (ja) | 2018-09-26 | 2024-05-16 | アステラス製薬株式会社 | 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬 |
| MX2021003765A (es) | 2018-10-03 | 2021-07-15 | Xencor Inc | Proteínas il-12 de fusión a fc heterodimérico. |
| KR102524247B1 (ko) | 2018-12-21 | 2023-04-21 | 가톨릭대학교 산학협력단 | p40-EBI3의 복합체 및 이의 용도 |
| GB2700048B (en) | 2019-09-18 | 2026-03-04 | Aldevron Llc | synthetic dna vectors and method of use |
| EP4037700A2 (en) | 2019-10-03 | 2022-08-10 | Xencor, Inc. | Targeted il-12 heterodimeric fc-fusion proteins |
| CN110777115B (zh) * | 2019-11-21 | 2020-08-21 | 北京启辰生生物科技有限公司 | 用于促进辅助T细胞产生TNF-α细胞因子的工程化DC细胞及方法 |
| CA3186753A1 (en) | 2020-07-20 | 2022-01-27 | John Mumm | Dual cytokine fusion proteins comprising il-10 |
| AU2022410872A1 (en) * | 2021-12-13 | 2024-07-11 | Deka Biosciences, Inc. | Dual cytokine fusion proteins comprising multi-subunit cytokines |
| EP4448724A4 (en) * | 2021-12-17 | 2025-12-10 | Univ Rice William M | Encapsulated cells expressing IL-12 and their uses |
| CN116621966B (zh) * | 2022-05-06 | 2026-01-27 | 珠海丽凡达生物技术有限公司 | 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用 |
| EP4534099A1 (en) * | 2022-05-27 | 2025-04-09 | Beijing Tianyifang Bio. Dev. Co., Ltd. | Production method for proliferative myeloid cells that constitutively produce il-12p70 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US5223424A (en) | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
| US5310668A (en) | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
| US5242829A (en) | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
| US5294441A (en) | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
| US5387744A (en) | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
| IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
| US5112749A (en) | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
| AU625584B2 (en) | 1989-03-08 | 1992-07-16 | Health Research Inc. | Recombinant poxvirus host selection system |
| US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| DE69027313T2 (de) | 1989-03-31 | 1997-01-23 | Univ Washington | Impfstoffe enthaltende avirulente phop-type mikroorganismen |
| ES2070997T3 (es) | 1989-12-04 | 1995-06-16 | Akzo Nobel Nv | Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos. |
| US5294548A (en) | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
| US5462734A (en) | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
| US5240703A (en) | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
| CA2134773A1 (en) | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| IL108449A (en) | 1993-01-26 | 2011-09-27 | Weiner David B | Assemblies and methods for delivery of genetic material |
| US5571515A (en) | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
| GB9505784D0 (en) * | 1995-03-22 | 1995-05-10 | Lynxvale Ltd | Anti-tumour treatment |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| CA2268276A1 (en) * | 1996-10-18 | 1998-04-30 | Jeff Nordstrom | Gene expression and delivery systems and uses |
| DK1023107T3 (da) | 1997-04-03 | 2006-12-27 | Electrofect As | Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| HUP0004589A3 (en) | 1997-06-30 | 2003-08-28 | Centre Nat Rech Scient | Improved method for transferring nucleic acid into the striped muscle and combination therefor |
| CA2323604A1 (en) * | 1998-03-19 | 1999-09-23 | Valentis, Inc. | Interferon alpha plasmids and delivery systems, and methods of making and using the same |
| US6697669B2 (en) | 1998-07-13 | 2004-02-24 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| US20030181405A1 (en) | 1999-03-12 | 2003-09-25 | Nordstrom Jeffrey L. | Interferon alpha plasmids and delivery systems, and methods of making and using the same |
| JP3543326B2 (ja) | 2001-08-30 | 2004-07-14 | ソニー株式会社 | 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| CA2504593C (en) | 2002-11-04 | 2016-08-09 | Advisys, Inc. | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
| ES2748130T3 (es) | 2003-05-30 | 2020-03-13 | Vgxi Inc | Dispositivos y métodos para la producción de un biomaterial |
| KR20060031610A (ko) * | 2003-05-30 | 2006-04-12 | 유니버시티 오브 사우스 플로리다 | 악성 종양 치료 방법 |
| US7833754B2 (en) * | 2006-01-13 | 2010-11-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | IL-12 for expression in mammalian cell |
| WO2008089144A2 (en) * | 2007-01-12 | 2008-07-24 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Improved dna vaccination protocols |
| EP2424887B1 (en) * | 2009-04-30 | 2015-09-30 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inducible interleukin-12 |
| EP2791157A4 (en) | 2011-12-12 | 2015-10-14 | Univ Pennsylvania | COMPOSITIONS WITH IMPROVED GENETIC IL-12 CONSTRUCTS AND VACCINES, IMMUNOTHERAPY THEREOF AND METHOD OF USE THEREOF |
| GB2504774A (en) | 2012-08-10 | 2014-02-12 | Munster Simms Eng Ltd | Diaphragm pump with integral motor housing and rear pump housing |
| TWI548337B (zh) | 2015-10-16 | 2016-09-01 | 技嘉科技股份有限公司 | 散熱模組、顯示卡組件及電子裝置 |
-
2012
- 2012-12-11 EP EP12857726.9A patent/EP2791157A4/en not_active Ceased
- 2012-12-11 US US14/365,086 patent/US9272024B2/en active Active
- 2012-12-11 EP EP17201202.3A patent/EP3336096A1/en active Pending
- 2012-12-11 AU AU2012352457A patent/AU2012352457B2/en active Active
- 2012-12-11 KR KR1020147019094A patent/KR102101819B1/ko active Active
- 2012-12-11 KR KR1020247019230A patent/KR20240096837A/ko active Pending
- 2012-12-11 CA CA2858893A patent/CA2858893A1/en active Pending
- 2012-12-11 KR KR1020227031904A patent/KR102674807B1/ko active Active
- 2012-12-11 JP JP2014547353A patent/JP6333730B2/ja active Active
- 2012-12-11 KR KR1020217021512A patent/KR102445129B1/ko active Active
- 2012-12-11 BR BR112014014078-2A patent/BR112014014078A2/pt not_active Application Discontinuation
- 2012-12-11 WO PCT/US2012/069017 patent/WO2013090296A1/en not_active Ceased
- 2012-12-11 KR KR1020207010487A patent/KR102277469B1/ko active Active
- 2012-12-11 EA EA201491171A patent/EA026926B1/ru not_active IP Right Cessation
- 2012-12-11 CN CN201280069473.6A patent/CN104245719B/zh active Active
- 2012-12-11 MX MX2014006987A patent/MX354986B/es active IP Right Grant
-
2014
- 2014-06-06 ZA ZA2014/04199A patent/ZA201404199B/en unknown
- 2014-06-11 MX MX2020001385A patent/MX2020001385A/es unknown
-
2016
- 2016-02-26 US US15/055,002 patent/US9981036B2/en active Active
-
2018
- 2018-04-25 JP JP2018084090A patent/JP6803354B2/ja active Active
- 2018-05-09 US US15/974,982 patent/US11241496B2/en active Active
-
2020
- 2020-11-30 JP JP2020198052A patent/JP7129106B2/ja active Active
-
2021
- 2021-12-28 US US17/563,392 patent/US20220193230A1/en active Pending
-
2022
- 2022-08-15 JP JP2022129334A patent/JP2022160704A/ja not_active Withdrawn
-
2024
- 2024-07-08 JP JP2024109421A patent/JP2024138373A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015501840A5 (enExample) | ||
| JP6957580B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| JP2015501656A5 (enExample) | ||
| JP2014507146A5 (enExample) | ||
| JP2009544333A5 (enExample) | ||
| FI3872085T3 (fi) | Esimuotoiset virussekvenssit ja niiden käytöt | |
| JP2014502156A5 (enExample) | ||
| EP3199545A3 (en) | Computationally optimized broadly reactive antigens for h1n1 influenza | |
| JP2019506175A5 (enExample) | ||
| BRPI0417509A (pt) | molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira | |
| JP2012515557A5 (enExample) | ||
| JP2014534202A5 (enExample) | ||
| JP2017532966A5 (enExample) | ||
| JP2013507907A5 (enExample) | ||
| JP2019530462A5 (enExample) | ||
| HRP20171213T1 (hr) | Glikoproteinske čestice nalik virusu (vlp) bjesnoće | |
| RU2015135890A (ru) | Композиция вакцины | |
| JP2009523422A5 (enExample) | ||
| JP2016533332A5 (enExample) | ||
| JP2009540801A5 (enExample) | ||
| EA202090738A1 (ru) | Способ безопасного индуцирования иммунитета против rsv | |
| MX2021015465A (es) | Vacuna para fiebre porcina africana. | |
| JP2015506705A5 (enExample) | ||
| JP2015524422A5 (enExample) | ||
| BR112014018884A2 (pt) | antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b |